Lucentis (Ranibizumab) Market Research Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts, 2019-2024, 2024-2029F, 2034F
Dublin, May 15, 2025 (GLOBE NEWSWIRE) -- The "Lucentis (Ranibizumab) Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts" report has been added to ResearchAndMarkets.com's offering.This Lucentis (Ranibizumab) market report delivers an in-depth analysis of the market's key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.
Major players operating in the lucentis (ranibizumab) market are F.Hoffmann-La Roche Ltd, Novartis AG. North America was the largest region in the lucentis (ranibizumab) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in lucentis (ranibizumab) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the lucentis (ranibizumab) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.The growth in the historic period can be attributed to the growing prevalence of age-related macular degeneration (AMD), approval and reimbursement by regulatory authorities, demonstrated efficacy and clinical outcomes, strong brand recognition, and physician adoption of Lucentis. The emergence of biosimilars and increased cost competition also played a significant role in driving market expansion.Market growth during the forecast period can be attributed to the increasing incidence of diabetic retinopathy (DR) and diabetic macular edema (DME), advancements in treatment protocols and combination therapies, and the aging population contributing to a rising prevalence of retinal diseases. Additionally, expanding market access in emerging markets, ongoing clinical research, and the potential for new indications will boost growth. Major trends in the forecast period include a shift toward longer-interval dosing and maintenance treatment, growing adoption of biosimilars and alternative treatments, the rise of personalized medicine approaches for retinal diseases, increased demand in emerging markets due to improving healthcare access, and the integration of digital health solutions in treatment monitoring.
The rising prevalence of eye-related disorders is expected to drive the growth of the lucentis (ranibizumab) market. Eye-related disorders encompass various conditions that impair the proper functioning of the eyes, and their prevalence is increasing due to factors such as aging, genetic predisposition, lifestyle choices like smoking and poor diet, and environmental influences such as prolonged sun exposure and excessive digital screen use.
Lucentis works by inhibiting vascular endothelial growth factor (VEGF), which is responsible for abnormal blood vessel growth and leakage in the retina, common causes of conditions like age-related macular degeneration (AMD) and diabetic macular edema (DME). According to the National Eye Institute, 2.2 million Americans will be blind by 2030, indicating a growing need for treatments like Lucentis. Thus, the rising prevalence of eye-related disorders is driving the market for lucentis.The rise in healthcare spending is a key factor propelling the growth of the lucentis (ranibizumab) market. Healthcare spending, which includes financial resources allocated by individuals, governments, and insurers for healthcare services and products, is increasing due to factors like an aging population, advancements in medical technology, and the rising prevalence of chronic diseases.
This growth in healthcare expenditure helps to ensure that treatments like Lucentis are accessible, enabling widespread use in treating retinal diseases such as AMD and DME. It also supports the reimbursement, coverage, and distribution of the drug, ultimately improving patient outcomes and reducing the long-term burden of vision loss. For instance, healthcare spending in the UK increased by 5.6% in 2023, reflecting a larger trend of rising healthcare investments that support the lucentis market.A key trend in the lucentis (ranibizumab) market is the development of biosimilars to offer more affordable alternatives to the branded product. Biosimilars are biologic medical products that are highly similar to an already approved reference biologic in terms of structure, efficacy, and safety, with no clinically meaningful differences.
For example, in April 2024, Formycon AG and Bioeq AG launched FYB201, a biosimilar version of Lucentis, in Canada and Switzerland. Known as Ranopto and Ranivisio in these markets, respectively, the biosimilar provides a more cost-effective option for patients suffering from retinal diseases. Like Lucentis, FYB201 inhibits VEGF-A, a protein that causes abnormal blood vessel growth in the retina, leading to conditions like swelling and vision impairment. The approval and launch of such biosimilars contribute to market growth by expanding access to treatment.Key Topics Covered: 1. Executive Summary2. Lucentis (Ranibizumab) Market Characteristics3. Lucentis (Ranibizumab) Market Biologic Drug Characteristics3.1. Molecule Type3.2. Route of Administration (ROA)3.3. Mechanism of Action (MOA)3.4. Safety and Efficacy4. Lucentis (Ranibizumab) Market Trends and Strategies5. Lucentis (Ranibizumab) Market - Macro Economic Scenario Macro Economic Scenario Including the Impact of Interest Rates, Inflation, Geopolitics, and the Recovery from COVID-19 on the Market6. Global Lucentis (Ranibizumab) Growth Analysis and Strategic Analysis Framework6.1. Global Lucentis (Ranibizumab) PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)6.2. Analysis of End Use Industries6.3. Global Lucentis (Ranibizumab) Market Growth Rate Analysis6.4. Global Lucentis (Ranibizumab) Historic Market Size and Growth, 2019-2024, Value ($ Billion)6.5. Global Lucentis (Ranibizumab) Forecast Market Size and Growth, 2024-2029, 2034F, Value ($ Billion)6.6. Global Lucentis (Ranibizumab) Total Addressable Market (TAM)7. Global Lucentis (Ranibizumab) Market Pricing Analysis & Forecasts8. Lucentis (Ranibizumab) Market Segmentation8.1. Global Lucentis (Ranibizumab) Market, Segmentation by Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Single-use Prefilled Syringe
Single-use Glass Vial
8.2. Global Lucentis (Ranibizumab) Market, Segmentation by Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Age-related Macular Degeneration
Diabetic Retinopathy
Retinal Vein Occlusion
Myopic Choroidal Neovascularization
Uveitis
8.3. Global Lucentis (Ranibizumab) Market, Segmentation by End-User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
Hospitals
Clinics
Ambulatory Surgical Centers
Other End-Users
9. Global Lucentis (Ranibizumab) Market Epidemiology of Clinical Indications9.1. Drug Side Effects9.2. Incidence and Prevalence of Clinical Indications10. Lucentis (Ranibizumab) Market Regional and Country Analysis10.1. Global Lucentis (Ranibizumab) Market, Split by Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion10.2. Global Lucentis (Ranibizumab) Market, Split by Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
For more information about this report visit https://www.researchandmarkets.com/r/rpmpk8
About ResearchAndMarkets.comResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
an hour ago
- Yahoo
Osisko Development Files NI 43-101 Feasibility Study Technical Report for the Cariboo Gold Project
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") announces the filing of a technical report (the "Technical Report") prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101") in respect of the feasibility study ("2025 FS") for its permitted, 100%-owned Cariboo Gold Project (the "Cariboo Gold Project"), located in central British Columbia, Canada. The Technical Report, titled "NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia, Canada" and dated June 11, 2025 (with an effective date of April 25, 2025), was prepared in accordance with NI 43-101 by independent representatives of BBA Engineering Ltd., as lead independent consultant, and supported by other independent engineering firms, including InnovExplo Inc., Alius Mine Consulting Ltd., Falkirk Environmental Consultants Ltd., WSP Canada Inc., M.A. O'Kane Consultants Inc., Integrated Sustainability Consultants Ltd., Clean Energy Consulting Inc., and JDS Energy & Mining Inc., each of whom is a "qualified person" (within the meaning of NI 43-101) and independent of Osisko Development (within the meaning of Section 1.5 of NI 43-101). The Technical Report supports the disclosure made by the Company in its news release dated April 28, 2025 (titled "Osisko Development Announces Optimized Feasibility Study for Permitted Cariboo Gold Project with C$943 Million After-Tax NPV5% and 22.1% IRR at US$2,400/oz Base Case Gold Price; at US$3,300/oz Spot Gold C$2.1 Billion After-Tax NPV5% and 38.0% IRR") announcing the results of the 2025 FS. The Technical Report supersedes the technical report titled "NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia" (as amended) dated January 12, 2023 (with an effective date of December 30, 2022), which should no longer be replied upon. The Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. Reference should be made to the full text of the Technical Report, including all assumptions, qualifications and limitations therein, which is available electronically on SEDAR+ ( and on EDGAR ( under Osisko Development's issuer profile and on the Company's website at ABOUT OSISKO DEVELOPMENT CORP. Osisko Development Corp. is a continental North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company's objective is to become an intermediate gold producer by advancing its flagship permitted 100%-owned Cariboo Gold Project, located in central B.C., Canada. Its project pipeline is complemented by the Tintic Project in the historic East Tintic mining district in Utah, U.S.A., and the San Antonio Gold Project in Sonora, Mexico—brownfield properties with significant exploration potential, extensive historical mining data, access to existing infrastructure and skilled labour. The Company's strategy is to develop attractive, long-life, socially and environmentally responsible mining assets, while minimizing exposure to development risk and growing mineral resources. For further information, visit our website at or contact: Sean Roosen Philip Rabenok Chairman and CEO Vice President, Investor Relations Email: sroosen@ Email: prabenok@ Tel: +1 (514) 940-0685 Tel: +1 (437) 423-3644 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
Yahoo
an hour ago
- Yahoo
Nusano Announces Breakthrough HALEU Program Expected to Produce Up to 350 Metric Tons of Fuel Annually for Advanced Nuclear Reactors
Reservations available now, commercial production deliveries begin Q1 2027 Proprietary process with reduced environmental impacts Efficient domestic supply chain needed to support projected growth in energy demand from increased electrification and energy-intensive industries Critical step toward energy independence being built in Utah WEST VALLEY CITY, Utah, June 11, 2025 (GLOBE NEWSWIRE) -- Nusano, a physics company transforming radioisotope production and enabling next-generation energy solutions, announced today the launch of a High-Assay Low-Enriched Uranium (HALEU) production program to support the need for new, sustainable energy solutions and small modular nuclear reactor (SMR) infrastructure in the United States. 'Domestic HALEU production is essential to enabling sustainable energy solutions,' said Chris Lowe, CEO of Nusano. 'Through our HALEU program, Nusano is working to stabilize supply chains, significantly drive down the cost of fuel, and enable the deployment of advanced nuclear energy on a scale needed to support advancements in AI, data centers, electrification, and modern logistics.' The Nusano HALEU program is a critical step toward establishing a 100% domestic fuel supply for next-generation energy solutions and firmly positions Utah to lead the nation in advanced fuel production. The launch also aligns with Utah Governor Cox's broader Operation Gigawatt strategy for energy abundance founded in a secure, stable and independent energy ecosystem, as well as recent federal government directives to build a domestic uranium enrichment supply. 'Utah has long played a role in the nation's nuclear fuel supply chain,' said Emy Lesofski, energy advisor to the governor and director of the Utah Office of Energy Development. 'As we explore how to meet the energy needs of the future, we're focused on energy resources that are reliable and clean—many of which need HALEU. The next generation of advanced nuclear technologies need fuel and companies like Nusano can fill that need safely and responsibly and we look forward to opportunities to partner with them at the Utah San Rafael Energy Lab.' Proprietary System Enables Mass Production Nusano brings new solutions to HALEU production, making it the first private company in the United States to offer a scalable, commercial solution for nuclear fuel with a focus on HALEU. The Nusano HALEU program utilizes a proprietary process capable of quick, cost-effective production and scale up. Compared to modern centrifuge facilities, the Nusano solution is more energy efficient, easier to operate, and can produce on demand—overcoming the most common issues associated with gas centrifuge machines. Additionally, Nusano's process eliminates the need for uranium hexafluoride, a bottleneck in current nuclear fuel cycles. These capabilities position Nusano to play a critical role stabilizing the domestic HALEU supply chain while also reducing environmental impacts. A stable, domestic fuel supply will ultimately decrease U.S. dependence on foreign suppliers, increasing our national security and economic stability. Nusano intends to produce initial commercial samples of HALEU by Q4 2026 and begin large scale production in Q1 2027. A single Nusano system will be capable of producing more than 50 metric tons of HALEU annually — with a small footprint, lower initial capital investment, and lower operating costs than other proposed solutions. Nusano plans to scale its production to approximately 350 metric tons annually by 2029. America's Unmet Energy Needs The United States Department of Energy estimates that by 2035, the country will need 50 metric tons per year of HALEU to support its commercial nuclear power industry, escalating to 500 metric tons per year by 2050. Current solutions are capable of providing less than 1% of that supply, which makes this project essential if America is to regain its energy independence and stabilize its economies. HALEU is a crucial fuel for small modular reactors (SMRs) and other advanced nuclear reactor designs. Unlike traditional reactors, which use uranium-235 (U-235) enriched to about 3-5%, HALEU is enriched to between 5-19.9% U-235, which allows for greater fuel efficiency, longer operational cycles, and more compact reactor designs. The Nuclear Regulatory Commission (NRC) oversees the establishment of new uranium facilities and the uranium enrichment process. The U.S. has been safely enriching uranium for decades and this project will continue the country's successful and responsible production of nuclear fuel. About NusanoNusano is a privately held physics company committed to: bringing supply stability and innovation to the rapidly emerging and critically undersupplied medical radioisotopes market, serving industrial and commercial markets dependent on reliable access to high quality radioisotopes for their products and services, and enabling next-generation energy solutions. Nusano's breakthrough technologies are poised to help supply the fight against cancer and enable innovation across multiple industries. For more, please visit Contacts: Media: Scott Larrivee, Nusano, 608-345-6629, Investor Relations: Joyce Allaire, LifeSci Advisors, LLC, 212-915-2569, jallaire@ in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Osisko Development Files NI 43-101 Feasibility Study Technical Report for the Cariboo Gold Project
MONTREAL, June 11, 2025 (GLOBE NEWSWIRE) -- Osisko Development Corp. (NYSE: ODV, TSXV: ODV) ("Osisko Development" or the "Company") announces the filing of a technical report (the "Technical Report") prepared in accordance with National Instrument 43-101 – Standards of Disclosure for Mineral Projects ("NI 43-101") in respect of the feasibility study ("2025 FS") for its permitted, 100%-owned Cariboo Gold Project (the "Cariboo Gold Project"), located in central British Columbia, Canada. The Technical Report, titled "NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia, Canada" and dated June 11, 2025 (with an effective date of April 25, 2025), was prepared in accordance with NI 43-101 by independent representatives of BBA Engineering Ltd., as lead independent consultant, and supported by other independent engineering firms, including InnovExplo Inc., Alius Mine Consulting Ltd., Falkirk Environmental Consultants Ltd., WSP Canada Inc., M.A. O'Kane Consultants Inc., Integrated Sustainability Consultants Ltd., Clean Energy Consulting Inc., and JDS Energy & Mining Inc., each of whom is a "qualified person" (within the meaning of NI 43-101) and independent of Osisko Development (within the meaning of Section 1.5 of NI 43-101). The Technical Report supports the disclosure made by the Company in its news release dated April 28, 2025 (titled "Osisko Development Announces Optimized Feasibility Study for Permitted Cariboo Gold Project with C$943 Million After-Tax NPV5% and 22.1% IRR at US$2,400/oz Base Case Gold Price; at US$3,300/oz Spot Gold C$2.1 Billion After-Tax NPV5% and 38.0% IRR") announcing the results of the 2025 FS. The Technical Report supersedes the technical report titled "NI 43-101 Technical Report, Feasibility Study for the Cariboo Gold Project, District of Wells, British Columbia" (as amended) dated January 12, 2023 (with an effective date of December 30, 2022), which should no longer be replied upon. The Technical Report is intended to be read as a whole, and sections should not be read or relied upon out of context. Reference should be made to the full text of the Technical Report, including all assumptions, qualifications and limitations therein, which is available electronically on SEDAR+ ( and on EDGAR ( under Osisko Development's issuer profile and on the Company's website at ABOUT OSISKO DEVELOPMENT CORP. Osisko Development Corp. is a continental North American gold development company focused on past-producing mining camps located in mining friendly jurisdictions with district scale potential. The Company's objective is to become an intermediate gold producer by advancing its flagship permitted 100%-owned Cariboo Gold Project, located in central B.C., Canada. Its project pipeline is complemented by the Tintic Project in the historic East Tintic mining district in Utah, U.S.A., and the San Antonio Gold Project in Sonora, Mexico—brownfield properties with significant exploration potential, extensive historical mining data, access to existing infrastructure and skilled labour. The Company's strategy is to develop attractive, long-life, socially and environmentally responsible mining assets, while minimizing exposure to development risk and growing mineral resources. For further information, visit our website at or contact: Sean Roosen Philip Rabenok Chairman and CEO Vice President, Investor Relations Email: sroosen@ Email: prabenok@ Tel: +1 (514) 940-0685 Tel: +1 (437) 423-3644 Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this news release. No stock exchange, securities commission or other regulatory authority has approved or disapproved the information contained herein.
